-+ 0.00%
-+ 0.00%
-+ 0.00%

Biocon Wins US FDA Approval for Pebrilzo Breast Cancer Biosimilar

PUBT·11/16/2026 03:10:58
Listen to the news
Biocon Wins US FDA Approval for Pebrilzo Breast Cancer Biosimilar
  • Biocon Biologics secured U.S. FDA approval for Pebrilzo, a biosimilar to Perjeta for treating HER2-positive breast cancer.
  • The earliest licensed U.S. launch is in the third quarter of 2028 under a settlement with Genentech.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 03PL6N68SYEINWKH) on November 16, 2026, and is solely responsible for the information contained therein.